App-Quantinova.ai

Incorrect specimen collection for investigation of cryoproteins can give mis‐leading results

F. Willis - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Monoclonal gammopathy

Lanthanum carbonate

Implementing a remote monitoring clinic for patients with stage A CLL

R. Bowen - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

N/A

Audit of invasive fungal disease (IFD) in paediatric haematopoietic stem cell transplant (HSCT) recipients and compliance with a national guideline for the diagnosis, prevention and treatment of fungal infections during paediatric HSCT; the Royal Marsden Hospital (RMH) experience 2018–2019

O. Tatarinova - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Nephrotoxicity

Anidulafungin

Efficacy and Safety of CPX‐351 Versus 7+3 In a Subgroup of Older Adults With Newly Diagnosed Acute Myeloid Leukemia With Myelodysplasia‐Related Changes (AML‐MRC) Enrolled In A Phase 3 Study

D.H. Ryan - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myeloid neoplasms

Daunorubicin

Validating Whole Genome Sequencing (WGS) for clinical use in AML & ALL

S. Henderson - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Methadone hydrochloride

CD200 blocking antibody restores immune functions and reduces disease levels in preclinical acute myeloid leukaemia models

N. Rastogi - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

Targeting H3K9me3 as novel therapeutic strategy in MLLr‐AML

M.E. Massett - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Acute myelocytic leukemia

N/A

Targeting metabolic vulnerabilities and aberrant signal transduction pathways in paediatric T‐cell Acute Lymphoblastic Leukaemia (T‐ALL)

L. Anselmi - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

T-cell acute lymphoblastic leukemia

N/A

Inhibition of C3 with APL‐2 Results in Normalisation of Markers of Intravascular and Extravascular Haemolysis in Patients with Paroxysmal Nocturnal Haemoglobinuria

R. Wong - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Paroxysmal nocturnal hemoglobinuria

Eculizumab

Rare variants in IKAROS family zinc finger 5 are responsible for autosomal dominant thrombocytopenia

C. Lentaigne - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Thrombocytopenia

N/A

A Retrospective Real World Evidence Study To Review The Current Treatment Pathways for Myelofibrosis From Across The United Kingdom (The REALISM UK Study)

A. Mead - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myelofibrosis

Hydroxycarbamide

A HaemSTAR‐led, UK‐wide “Flash‐Mob” audit of intravenous immunoglobulin use in immune thrombocytopenia

P.L. Nicolson - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Immune thrombocytopenia

IVIG

CIP2A regulates PP2A by altering the profile of PP2A B subunits

J. Austin - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Should we write clinic letters directly to patients? An audit and survey of current practice and opinion at Barts Health haematology department

N. Joshi - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Improving transfusion education using technology enhanced learning–success of ‘Transfusion in Practice’; an innovative national transfusion course

J. Graham - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Methadone hydrochloride

Audit of 24 months of experience using Obinutuzumab and Chlorambucil Treatment for Chronic Lymphocytic Leukaemia at the University Hospital of Wales, Cardiff; Assessing its suitability for use in a nurse led off‐site service

C. Bloodworth - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Obinutuzumab

A quality improvement project to increase risk assessment for Venous Thromboembolism (VTE) to meet a national target in a large teaching hospital

H. Rowswell - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Venous thrombosis

N/A

Clinical Utility of The Serum Free Light Chain Assay in Primary Care

C. Lodwick - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Monoclonal gammopathy

Lanthanum carbonate

Introducing Self Administration of Bortezomib (Velcade) to Myeloma Patients

T. Burton - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Peripheral Nervous System

Peripheral neuropathy

Bortezomib

Preventing and repairing myeloma bone disease by combining zoledronic acid with TGFβ inhibition therapy

J. Paton-Hough - British Society for Hematology (BSH) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Zoledronic acid

Filters

45280 Abstracts